[Double blind test of the effect of sulpiride. A new antivertiginous agent].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
K Sveen
Publications and source records attributed to K Sveen.
Use of preformed cavities in rabbits for the quantitation of leukocyte chemotaxis caused by bacterial lipopolysaccharides.
Wound chambers implanted subcutaneously in rabbits proved suitable for measurements of leukocyte chemotaxis. Injection of bacterial lipopolysaccharide (LPS) in the chambers the sixth day after implantation was followed by a marked increase of polymorphonuclear leukocytes in the wound chamber fluid, the number of which was dependent on the time after application of LPS. Up to a certain amount of LPS, the concentration of leukocytes in the chamber fluid was dose-dependent. The histopathological appearance of the granulation tissue lining the chamber wall one day after the injection of LPS from Veillonella revealed aggregation of blood cells plugging the lumina of small vessels and many eosinophilic leukocytes.
Animals↗
Influence of the cation on the side-effects of urographic contrast media.
The incidence of side-effects produced by meglumine diatrizoate and meglumine-, meglumine-calcium-, and sodium-calcium-magnesium metrizoate, was compared in 800 urographies. Patients older than 60 years seem to have less side-effects than younger patients. The incidence of sensation of warmth seems to be higher in patients who have had previous urographies, compared to those who are examined for the first time. The incidence of this effect is higher for the sodium-calcium-magnesium salt of metrizoate, than for other salts of metrizoate.
Adult↗
Paracetamol/codeine in relieving pain following removal of impacted mandibular third molars.
A double-blind clinical study of analgesic drugs was conducted involving 47 healthy adults requiring removal of 90 bony impacted mandibular third molars. The analgesic effect of paracetamol plus codeine (P + C) 350 + 20 mg was compared to that of acetylsalicylic acid (ASA) 500 mg and placebo. A standardized surgical procedure under local anesthesia was used. Insufficient analgesic effect was noted in 16% of the ASA group and in 69% of the placebo group but in none in the P+C group. On the first postoperative day, patients given P+C suffered less pain compared with those given ASA (P less than 0.01). No relationship could be demonstrated between the type of impaction and intensity of pain. Trismus, however, was found to be associated with difficulty of extirpation. Drowsiness and an increased sleeping tendency were the main side effects found in the P+C group. The incidence of secondary hemorrhage was high in the ASA group, compared with the P+C group a significance of 0.01 less than P less than 0.05 was found on various postoperative days. Registration of swelling revealed less postoperative edema in the P+C group than in the ASA group (0.01less thanPless than0.05). The main conclusion from this study is that the analgesic effect of P+C orally administered after a specific oral surgical procedure is superior to ASA and placebo. P+C also appears to have a more marked antiphologistic effect than ASA.
Acetaminophen↗
[Myxomas in the jaw. A case of bilateral maxillary myxomas].
Explore the source record for details and available documents.
Child↗
[Foreign bodies in the maxillary sinus].
Explore the source record for details and available documents.
Female↗
The chemotactic effect of Bacteroides fragilis lipopolysaccharide.
The atypical Bacteroides fragilis lipopolysaccharide is chemotactic for polymorphonuclear leukocytes. The chemotactic activity is mediated by complement activated through the alternative pathway. This mediator has been isolated. It is a polypeptide with a molecular weight of 16,000 and is most likely the complement component C5a.
Animals↗
Amipaque (metrizamide) in vascular use and use in body cavities: a survey of the initial clinical trials.
A review of the initial 76 clinical trials with Amipaque in vascular radiology and in examinations of the body cavities, mostly performed in the Scandinavian countries, is given. The clinical material presented comprises a total of 2,661 Amipaque examinations, 1,784 examinations performed intravascularly and 515 in body cavities. In addition, 362 vascular examinations with Amipaque in children are presented. Generally, no difference in visualization compared to ionic media was found. However, improved visualization was reported in some few angiographic studies and higher contrast density was indicated in the urograms. Compared to ionic media, Amipaque caused considerably less subjective reactions and less hemodynamic effects. A remarkable reduction in post-phlebographic thrombosis following leg phlebography was found with Amipaque. No death related to Amipaque occurred, and few contrast medium reactions have been recorded. Thus, the good tolerability of the non-ionic Amipaque shown in animal studies has also been confirmed clinically outside the subarachnoid space.
Adult↗
Human pharmacokinetics of iohexol. A new nonionic contrast medium.
The pharmacokinetics of iohexol, a new nonionic, water-soluble contrast medium, have been determined after intravenous injection in 20 healthy volunteers, at four different dose levels (125-500 mg I/kg). The apparent volume of distribution was 0.27 1/kg, indicating distribution in the extracellular water. The biologic half-life was 121 minutes, comparable with that of other intravascular contrast media. Iohexol was excreted completely unmetabolized in the urine, with a 100% recovery 24 hours after injection. A comparison of iohexol and chromium-51 (51Cr)-EDTA clearances indicates that iohexol is mainly excreted by glomerular filtration. The 51Cr-EDTA clearance was the same when injected separately and concomitantly with iohexol, indicating that glomerular filtration rate is not affected by iohexol. No dose dependency was observed in the investigated parameters t1/2 alpha, t1/2 beta, Vd, ClT or ClR. Iohexol pharmacokinetics are in correspondence with previously reported data on intravascular contrast media.
Adolescent↗
High dose urography in patients with renal failure. A double blind investigation of iohexol and metrizoate.
The new non-ionic contrast medium iohexol 350 mg I/ml was compared with the ionic contrast medium metrizoate 350 mg I/ml in a double blind, two-group urographic study performed on 20 patients with stable, impaired renal function. A dose of contrast medium of 500 mg I/kg body weight was given to each patient. Iohexol resulted in significantly fewer subjective adverse reactions than metrizoate. A similar image quality was obtained with the two contrast media. No clinically significant difference existed between the two contrast media with respect to influence on blood pressure, pulse or clinical chemical parameters. A tendency to deterioration of renal function after urography was found in both groups, but no difference of statistical significance existed between the two contrast media with respect to possible nephrotoxicity. Inadequate hydration may have been partly responsible for the nephrotoxic effect of the urographic procedure.
Adult↗
Summary of U.S. and European intravascular experience with iohexol based on the clinical trial program.
The nonionic contrast medium, iohexol, was released by Nyegaard, Oslo, in 1980 for clinical testing. Results of a three-phase clinical trial program carried out in Europe and the U.S. through December 1983 are summarized. Evaluation of phase I studies of human tolerance and excretion--and phase II studies of effects on pharmacologic and physiologic parameters--indicated that iohexol was well tolerated and effective. Phase III consisted mainly of controlled parallel and crossover studies comparing iohexol with conventional ionic media and with other nonionic agents in a variety of radiographic studies. Image quality was as good or better with iohexol than with ionic media. Iohexol was tolerated significantly better than ionic agents. Patients consistently reported fewer and less intense pain and heat sensations. Iohexol had less effect on blood pressure, blood flow, heart rate, and electrophysiologic parameters, and caused fewer adverse reactions than ionic media for all types of reactions observed.
Clinical Trials as Topic↗
Randomized double-blind cross-over study of iohexol and Amipaque in cerebral angiography.
Iohexol was compared with Amipaque (metrizamide) in a double-blind study in one pair of injections in each of 20 patients referred for routine cerebral angiography. Catheter position, patient position, injection pressure, contrast medium volume, and concentration (300 mg l/ml) were the same in the two injections, with iohexol and Amipaque being used alternately. Except for these two injections iohexol was used throughout. The parameters studied included diagnostic information obtained (quality of the examination), circulation time, and comparison of patient reactions to the pair of injections (e.g., electrocardiogram, heart rate, and subjective reactions). The patients' reactions to the noncomparative part of the examination were evaluated also, and the patients were observed for possible adverse reactions after the examination. No difference could be detected between the two contrast media in this series. No serious adverse reactions occurred.
Adult↗